Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 217

Similar articles for PubMed (Select 10871316)

1.

An investigation of the uroselective properties of four novel alpha(1a)-adrenergic receptor subtype-selective antagonists.

Pulito VL, Li X, Varga SS, Mulcahy LS, Clark KS, Halbert SA, Reitz AB, Murray WV, Jolliffe LK.

J Pharmacol Exp Ther. 2000 Jul;294(1):224-9.

2.
3.

RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia.

Nanda K, Naruganahalli KS, Gupta S, Malhotra S, Tiwari A, Hegde LG, Jain S, Sinha N, Gupta JB, Chugh A, Anand N, Ray A.

Eur J Pharmacol. 2009 Apr 1;607(1-3):213-9. doi: 10.1016/j.ejphar.2009.02.026. Epub 2009 Feb 23.

PMID:
19239913
4.

Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.

Kuo GH, Prouty C, Murray WV, Pulito V, Jolliffe L, Cheung P, Varga S, Evangelisto M, Wang J.

J Med Chem. 2000 Jun 1;43(11):2183-95.

PMID:
10841797
5.

Preclinical pharmacology of fiduxosin, a novel alpha(1)-adrenoceptor antagonist with uroselective properties.

Hancock AA, Buckner SA, Brune ME, Esbenshade TA, Ireland LM, Katwala S, Milicic I, Meyer MD, Kerwin JF Jr, Williams M.

J Pharmacol Exp Ther. 2002 Feb;300(2):478-86.

6.

Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I.

Leonardi A, Hieble JP, Guarneri L, Naselsky DP, Poggesi E, Sironi G, Sulpizio AC, Testa R.

J Pharmacol Exp Ther. 1997 Jun;281(3):1272-83.

7.
8.

Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs.

Brune ME, Katwala SP, Milicic I, Witte DG, Kerwin JF Jr, Meyer MD, Hancock AA, Williams M.

J Pharmacol Exp Ther. 2002 Feb;300(2):487-94.

9.

Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists.

Witte DG, Brune ME, Katwala SP, Milicic I, Stolarik D, Hui YH, Marsh KC, Kerwin JF Jr, Meyer MD, Hancock AA.

J Pharmacol Exp Ther. 2002 Feb;300(2):495-504.

10.

Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.

Nagarathnam D, Wetzel JM, Miao SW, Marzabadi MR, Chiu G, Wong WC, Hong X, Fang J, Forray C, Branchek TA, Heydorn WE, Chang RS, Broten T, Schorn TW, Gluchowski C.

J Med Chem. 1998 Dec 17;41(26):5320-33.

PMID:
9857099
11.

Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 2. Approaches to eliminate opioid agonist metabolites via modification of linker and 4-methoxycarbonyl-4-phenylpiperidine moiety.

Murali Dhar TG, Nagarathnam D, Marzabadi MR, Lagu B, Wong WC, Chiu G, Tyagarajan S, Miao SW, Zhang F, Sun W, Tian D, Shen Q, Zhang J, Wetzel JM, Forray C, Chang RS, Broten TP, Schorn TW, Chen TB, O'Malley S, Ransom R, Schneck K, Bendesky R, Harrell CM, Vyas KP, et al.

J Med Chem. 1999 Nov 18;42(23):4778-93.

PMID:
10579841
13.

Effect of alpha 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog.

Kenny BA, Naylor AM, Carter AJ, Read AM, Greengrass PM, Wyllie MG.

Urology. 1994 Jul;44(1):52-7.

PMID:
7913781
14.

Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists.

Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I.

J Pharmacol Exp Ther. 1997 Jul;282(1):228-35.

15.

Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs.

Suzuki Y, Kanada A, Okaya Y, Aisaka K.

Eur J Pharmacol. 2000 Apr 7;394(1):123-30.

PMID:
10771044
16.

A-61603, a potent alpha 1-adrenergic receptor agonist, selective for the alpha 1A receptor subtype.

Knepper SM, Buckner SA, Brune ME, DeBernardis JF, Meyer MD, Hancock AA.

J Pharmacol Exp Ther. 1995 Jul;274(1):97-103.

PMID:
7616455
17.

Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 1. Structure-activity relationship in dihydropyrimidinones.

Nagarathnam D, Miao SW, Lagu B, Chiu G, Fang J, Murali Dhar TG, Zhang J, Tyagarajan S, Marzabadi MR, Zhang F, Wong WC, Sun W, Tian D, Wetzel JM, Forray C, Chang RS, Broten TP, Ransom RW, Schorn TW, Chen TB, O'Malley S, Kling P, Schneck K, Bendesky R, Harrell CM, et al.

J Med Chem. 1999 Nov 18;42(23):4764-77.

PMID:
10579840
18.

Design, synthesis and biological evaluation of pyridine-phenylpiperazines: a novel series of potent and selective alpha1a-adrenergic receptor antagonist.

Kuo GH, Prouty C, Murray WV, Pulito V, Jolliffe L, Cheung P, Varga S, Evangelisto M, Shaw C.

Bioorg Med Chem. 2000 Sep;8(9):2263-75.

PMID:
11026539
19.

Synthesis, pharmacology and pharmacokinetics of 3-(4-aryl-piperazin-1-ylalkyl)-uracils as uroselective alpha1A-antagonists.

Lopez FJ, Arias L, Chan R, Clarke DE, Elworthy TR, Ford AP, Guzman A, Jaime-Figueroa S, Jasper JR, Morgans DJ Jr, Padilla F, Perez-Medrano A, Quintero C, Romero M, Sandoval L, Smith SA, Williams TJ, Blue DR.

Bioorg Med Chem Lett. 2003 Jun 2;13(11):1873-8.

PMID:
12749888
20.

In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia.

Barrow JC, Nantermet PG, Selnick HG, Glass KL, Rittle KE, Gilbert KF, Steele TG, Homnick CF, Freidinger RM, Ransom RW, Kling P, Reiss D, Broten TP, Schorn TW, Chang RS, O'Malley SS, Olah TV, Ellis JD, Barrish A, Kassahun K, Leppert P, Nagarathnam D, Forray C.

J Med Chem. 2000 Jul 13;43(14):2703-18.

PMID:
10893308
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk